---
document_datetime: 2023-09-21 19:47:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/cuprior-epar-all-authorised-presentations_en.pdf
document_name: cuprior-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8179989
conversion_datetime: 2025-12-29 22:05:29.804895
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form   | Route of Administration   | Immediate Packaging       | Pack size              |
|------------------|-------------------|------------|-----------------------|---------------------------|---------------------------|------------------------|
| EU/1/17/1199/001 | Cuprior           | 150 mg     | Film-coated tablet    | Oral use                  | blister (OPA/alu/PVC/alu) | 72 film-coated tablets |
| EU/1/17/1199/002 | Cuprior           | 150 mg     | Film-coated tablet    | Oral use                  | blister (OPA/alu/PVC/alu) | 96 film-coated tablets |